The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
May 16th 2024
This cross-sectional analysis demonstrates the impact that comorbidities in multiple sclerosis (MS) have on sleep quality in affected patients.
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
June 27, 2024 | 1:00 PM & 7:00 PM ET
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline
September 7th 2019The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably won’t come to market for at least another year and a half, said Daniel Kantor, MD, president of Kantor Neurology.
Watch
This Week in Managed Care: August 30, 2019
August 30th 2019This week, the top managed care stories included a huge ruling against one opioid maker and a settlement offer from another; an expert panel calling for broader screening for hepatitis C; a review showing there are more fatal events linked to a multiple sclerosis drug than previously known.
Watch
Despite More Competition, Medicare Costs for MS Drugs Rose Steadily Over 10 Years
August 27th 2019Even as more competition entered the market, the prices of self-administered disease-modifying therapies for multiple sclerosis (MS) rose steadily from 2006 to 2016, and seniors with Medicare Part D coverage saw a 7.2-fold increase in out-of-pocket costs.
Read More
Fatal AEs Associated With Alemtuzumab for MS May Occur More Frequently Than Previously Thought
August 23rd 2019Fatal adverse events (AEs) associated with alemtuzumab for multiple sclerosis (MS) may occur more frequently than previously understood based on past published literature, researchers found.
Read More
June Halper Describes the Team-Based Approach Underlying the Consortium of MS Centers
August 23rd 2019The Consortium of Multiple Sclerosis (MS) Centers is unique in that it places physicians and other healthcare professionals on a level playing field while elevating the patient’s voice to be the most important on the team, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.
Watch
June Halper on How Supportive Team Care Can Help Patients With MS as Their Disability Increases
August 15th 2019While there may be negative connotations attached to the term “palliative care,” this type of care could be called “supportive team care” to better express its potential to educate and care for patients with chronic illnesses such as multiple sclerosis (MS), said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.
Watch
Chronic Active Lesions Associated With Poorer Outcomes in Multiple Sclerosis
August 14th 2019Chronic active lesions, which are identified by their darkened outer rims, are associated with more aggressive multiple sclerosis and earlier disability, according to new research from the National Institute of Health.
Read More
Patients With MS Less Likely to Have Received Vaccinations Before MS Diagnosis
August 9th 2019In the 5 years before being diagnosed, patients with multiple sclerosis (MS) were less likely to receive vaccinations than comparator groups, according to a new study from the Technical University of Munich and published in Neurology.
Read More
June Halper Discusses the Importance of Shared Decision Making in MS Treatment
August 8th 2019Shared decision making has been taught to clinicians for years, but it is especially crucial when treating multiple sclerosis (MS) due to the importance of treatment adherence, according to June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.
Watch
Dr Patty Taddei-Allen Outlines the Importance of Adherence to MS Therapies
August 1st 2019Encouraging patient adherence to medication is very important to managing the cost of multiple sclerosis (MS) therapies, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director, outcomes research, WelldyneRx.
Watch
June Halper: The Role of Caregiver in MS Is Extremely Important
July 26th 2019Since multiple sclerosis is a chronic disease with no cure or control, the role of a caregiver or care partner is very important, said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.
Watch
Physical Disability, Executive Functioning Predict Employment Status in Patients With MS
July 24th 2019The likelihood of patients with multiple sclerosis (MS) maintaining their employment status in 2 years can be predicted by their levels of physical disability and executive functioning, but not by other measures of cognition, according to new study findings.
Read More
June Halper Emphasizes the Lack of Understanding of Causes of Multiple Sclerosis
July 17th 2019The cause of multiple sclerosis is not well understood. In fact, it’s not understood at all, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.
Watch
June Halper on Challenges With Identifying Which Multiple Sclerosis Treatments Have the Most Promise
July 9th 2019Identifying which treatments for multiple sclerosis have the most promise is challenging because there are no head-to-head studies comparing treatments and what's promising for one clinician is different than what's promising for another clinician, explained June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers.
Watch
Dr Mark Freedman Outlines the Precision Decision in Multiple Sclerosis Treatments
July 3rd 2019There are a lot of factors that should be considered when choosing a therapy for a patient with multiple sclerosis, including the patient profile, the patient’s lifestyle, and the efficacy of the therapy, said Mark Freedman, MD, MSc, professor of medicine in neurology at the University of Ottawa, director of the Multiple Sclerosis Research Unit, at Ottawa Hospital-General Campus, and senior scientists in the neuroscience program at Ottawa Hospital Research Institute.
Watch
Alemtuzumab Retained Long-Term Safety, Efficacy in Patients With Relapsing-Remitting MS of All Ages
June 16th 2019Alemtuzumab improved clinical and magnetic resonance imagining outcomes in patients with relapsing-remitting multiple sclerosis across varying age groups and maintained efficacy through year 8 of follow up.
Read More
FDA, EMA Accept Applications for Ozanimod to Treat Relapsing Forms of MS
June 13th 2019Both the FDA and the European Medicines Agency (EMA) have accepted applications to review ozanimod, an oral sphingosine 1-phosphate receptor modulator, for the treatment of relapsing forms of multiple sclerosis (MS).
Read More